BioCryst Pharmaceuticals is a Buy and 3 More Analyst Upgrades to Know

Stock upgrades and downgrades are a controversial part of Wall Street. Despite regulations, many banks and firms still have a positive bias toward current clients and companies desired as future clients. In addition, Wall Street analysts are straight-up biased to the buy side. The percentage of sell recommendations is normally below 15 percent!

Regardless, upgrades and downgrades move stocks in the short-term. They fall into our CHEAT SHEET framework category ‘C = Catalyst for a Stock?s Movement’. Here are catalysts you must know today:

BioCryst Pharmaceuticals (NASDAQ:BCRX): MLV Capital upgraded its rating on this company from Hold to Buy and changed its price target to $3.00.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

BCRX

African Barrick Gold (NYSE:ABG): Westhouse Securities upgraded its rating on this company to Neutral and changed its price target to $2.99.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

ABG

Apollo Residential Mortg (NYSE:AMTG): JPMorgan Chase upgraded its rating on this company from Neutral to Overweight.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

AMTG

BB&T (NYSE:BBT): Compass Point upgraded its rating on this company from Neutral to Buy and changed its price target from $34.00 to $38.00.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

BBT

Investing Insights: Will CVS Continue to Skyrocket?